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RESEARCH
Serum renin and major adverse kidney 
events in critically ill patients: a multicenter 
prospective study
Alexander H. Flannery1,2, Victor Ortiz‑Soriano3, Xilong Li4, Fabiola G. Gianella5, Robert D. Toto5,6, 
Orson W. Moe5,6, Prasad Devarajan7, Stuart L. Goldstein7 and Javier A. Neyra3,5*  
Abstract 
Background: Preliminary studies have suggested that the renin‑angiotensin system is activated in critical illness and 
associated with mortality and kidney outcomes. We sought to assess in a larger, multicenter study the relationship 
between serum renin and Major Adverse Kidney Events (MAKE) in intensive care unit (ICU) patients.
Methods: Prospective, multicenter study at two institutions of patients with and without acute kidney injury (AKI). 
Blood samples were collected for renin measurement a median of 2 days into the index ICU admission and 5–7 days 
later. The primary outcome was MAKE at hospital discharge, a composite of mortality, kidney replacement therapy, or 
reduced estimated glomerular filtration rate to ≤ 75% of baseline.
Results: Patients in the highest renin tertile were more severely ill overall, including more AKI, vasopressor‑depend‑
ence, and severity of illness. MAKE were significantly greater in the highest renin tertile compared to the first and 
second tertiles. In multivariable logistic regression, this initial measurement of renin remained significantly associated 
with both MAKE as well as the individual component of mortality. The association of renin with MAKE in survivors was 
not statistically significant. Renin measurements at the second time point were also higher in patients with MAKE. The 
trajectory of the renin measurements between time 1 and 2 was distinct when comparing death versus survival, but 
not when comparing MAKE versus those without.
Conclusions: In a broad cohort of critically ill patients, serum renin measured early in the ICU admission is associated 
with MAKE at discharge, particularly mortality.
Keywords: Renin, Acute kidney injury, Major adverse kidney events, Critical illness, Biomarker, Renin angiotensin 
system
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Background
The renin-angiotensin system (RAS) is increasingly rec-
ognized to be perturbed during critical illness. The com-
plexity of this system, including circulatory, tissue-level, 
and intra-cellular actions, as well as both traditional and 
counter-regulatory axes, makes it difficult to simply clas-
sify the RAS as activated or insufficiently activated in 
critical illness; rather, it is dysfunctional [1]. RAS pep-
tide analysis in vasodilatory shock [2] and acute respira-
tory distress syndrome [3] have strongly suggested a state 
of reduced angiotensin converting enzyme (ACE) and 
ACE2 function, respectively, which influences both the 
traditional and counter-regulatory axes of the RAS. Fur-
thermore, reduced ACE and ACE2 function are associ-
ated with acute kidney injury (AKI) [4] and mortality [3], 
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respectively, in critically ill patients. Biochemical evalua-
tion of the RAS requires careful biospecimen collection 
and sophisticated analytical techniques [5]. However, 
upstream in the complex milieu of RAS peptide metab-
olism, renin plays a rate-limiting step in the conversion 
of angiotensinogen to angiotensin I, and is a far more 
readily available lab test for clinicians to consider at the 
bedside.
Recently, a single center study showed that plasma 
renin outperformed lactate in prognostic value for inten-
sive care unit (ICU) mortality [6]. Subsequently, a small, 
single center study found no association of plasma renin 
with mortality, but did note plasma renin to be much 
higher with worsening AKI [7]. Given the potential of 
renin to serve as a novel biomarker for adverse kidney 
outcomes and mortality in critically ill patients, we con-
ducted a multicenter prospective study to examine the 
association of serum renin with mortality and adverse 
kidney events in a larger and heterogeneous cohort of 
critically ill adult patients.
Methods
This was a prospective, multicenter study of ICU 
patients from two academic medical centers. Patients 
were recruited sequentially from each site: University 
of Texas Southwestern (2015–2017) and the Univer-
sity of Kentucky (2017–2019). Adult patients ≥ 18  years 
old admitted to surgical, medical, or cardiac ICUs with 
a documented baseline estimated glomerular filtration 
rate (eGFR) ≥ 60 mL/min/1.73  m2 were eligible for inclu-
sion. eGFR was calculated using the most recent outpa-
tient serum creatinine in the 6 months prior to admission 
using the CKD-Epidemiology Collaboration equation [8]. 
Patients with end stage kidney disease (ESKD), evidence 
of AKI prior to ICU admission, uroepithelial tumors, or 
prior solid organ transplant were excluded.
The study purposefully included ICU patients with 
incident AKI based on Kidney Disease: Improving 
Global Outcomes (KDIGO) serum creatinine or urine 
output stage ≥ 2 criteria and ICU patients without AKI 
[9]. Blood samples were collected within the first 3 days 
of ICU admission (~ 24  h after AKI diagnosis for those 
with AKI). A second set of blood samples were collected 
5–7  days following the initial collection. Demographic 
and comorbidity data were collected from the patient’s 
medical record for each enrolled patient. ICU-centric 
therapies were assessed, including the need for mechani-
cal ventilation and vasopressor support. Patients’ comor-
bidities and severity of illness were further assessed with 
the Charlson Comorbidity Index [10] and Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) II score, 
respectively [11].
The primary outcome of the study was a major adverse 
kidney event (MAKE) by hospital discharge, defined as 
death, kidney replacement therapy (KRT) dependence 
at hospital discharge, or a reduction in eGFR to ≤ 75% of 
baseline at hospital discharge [12]. Each sub-component 
of the primary composite outcome was also assessed sep-
arately. Additional secondary outcomes included need 
for inpatient KRT, duration of mechanical ventilation, 
and ICU and hospital length of stay.
The study was approved by the institutional review 
boards at both participating centers. Patients, or their 
legally authorized representatives, provided written, 
informed consent for participation in the study.
Laboratory analysis
Serum samples were processed within 45–60  min of 
collection, centrifuged at 1000g at 4  °C for 10  min, and 
stored at − 80  °C. Renin measurements were obtained 
using the active renin ELISA kit from DRG Diagnostics 
(Kit Reference ID: EIA-5125). The assay dynamic range 
is 0.80–128.0  pg/ml. The intra-assay CV is 2.4% and 
the inter-assay CV is 3.7%. The expected normal val-
ues in the serum or plasma range from 2.5 to 49.3  pg/
ml. Neutrophil gelatinase-associated lipocalin (NGAL) 
measurements were obtained on a Siemens BNII using a 
particle-enhanced turbidimetric immunoassay from Bio-
Porto (The NGAL Test, Kit Reference ID: ST001). Most 
samples (> 90%) were measured on the first freeze–thaw 
cycle. All other laboratory data were extracted from 
routine measurements available in the electronic health 
record.
Statistical analysis
The first timepoint of renin measurements were assessed 
in tertiles. Medians and interquartile range and fre-
quency (proportions) were used to provide descriptive 
statistics for the cohort. Comparisons among groups 
were done with Kruskal–Wallis (3 groups) or Wilcoxon 
rank-sum (2 groups) for continuous data and chi-square 
test for categorical data.
For the primary outcome of MAKE, a logistic regres-
sion model was constructed using renin tertiles as the 
independent variable of interest. Additional variables 
to include in the model were identified by the study 
group based upon their hypothesized ability to influence 
MAKE and according to imbalances in clinical parame-
ters among renin tertiles that could potentially influence 
outcome. Given prior data demonstrating a strong asso-
ciation of serum NGAL with MAKE, including NGAL 
outperforming serum creatinine [13, 14], we used NGAL 
to adjust for the presence and severity of kidney injury. 
NGAL (and renin in the sensitivity analysis) were log-
transformed due to the skewness of the data. Additional 
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variables included in the model were: age, sex, race, 
baseline eGFR, Charlson Comorbidity Index, ICU type, 
study site, and non-renal APACHE II. In a pre-planned 
sensitivity analysis, renin was subsequently analyzed as 
a continuous variable in the logistic regression model 
for MAKE. Clinical parameters that were otherwise cap-
tured in scoring systems such as the Charlson Comorbid-
ity Index and APACHE II were not included in order to 
avoid collinearity, which was assessed in the final models 
using variance inflation factors. When analyzing indi-
vidual components of the MAKE outcome with logistic 
regression, we used backward stepwise regression (p < 0.2 
threshold) given that we anticipated the reduced number 
of events to not accommodate the number of covariates 
used in the primary model. Finally, a mixed linear model 
was used to examine repeated measures analysis of 
serum renin levels between the two time points and their 
association with MAKE and the individual component of 
mortality.
A two-sided p value ≤ 0.05 was considered statistically 
significant. Stata (StataCorp. 2019. Stata Statistical Soft-
ware: Release 16. College Station, TX: StataCorp LLC) 
and SAS 9.4 (SAS Institute, Cary, NC) were used for all 
statistical analyses.
Results
From January 2015 to September 2019, 280 patients 
were enrolled in this prospective study with available 
blood samples for analysis. The median time from ICU 
admission to initial sample collection in the cohort was 
2 (1–3) days. Baseline patient characteristics according 
to tertiles of serum renin are shown in Table 1. Seven 
Table 1 Patient characteristics by renin tertile at first measurement
ICU intensive care unit, eGFR estimated glomerular filtration rate, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure 
assessment, NGAL neutrophil gelatinase-associated lipocalin
a As percent of all acute kidney injury cases
Patient demographic Tertile 1 (n = 94) Tertile 2 (n = 93) Tertile 3 (n = 93) p value
Serum renin (pg/ml) 7.2 (3.1–12.4) 40.7 (29.9–60.1) 355.3 (180.4–1032.1) < 0.001
Age (years) 61.5 (47–71) 59 (50–66.5) 53 (40.5–64) 0.004
Sex (% male) 53 (56.4%) 53 (57.0%) 57 (61.3%) 0.760
Race (%) 0.649
 White 75 (79.8%) 74 (79.6%) 71 (76.3%)
 Black 10 (10.6%) 9 (9.7%) 7 (7.5%)
 Other 9 (9.6%) 10 (10.8%) 15 (16.1%)
Weight (kg) 77.7 (65.1–95.3) 88.0 (75.3–105.2) 89.8 (72.8–113.4) 0.006
ICU (%) 0.001
 Surgical 46 (48.9%) 37 (39.8%) 18 (19.4%)
 Medical 33 (35.1%) 34 (36.6%) 48 (51.6%)
 Cardiac 15 (16.0%) 22 (23.7%) 27 (29.0%)
Diabetes (%) 23 (24.5%) 26 (28.0%) 25 (26.9%) 0.858
Hypertension (%) 50 (53.2%) 47 (50.5%) 49 (52.7%) 0.928
Heart failure (%) 20 (21.3%) 20 (21.5%) 31 (33.3%) 0.096
Liver disease (%) 8 (8.5%) 14 (15.1%) 25 (26.9%) 0.003
Cancer (%) 28 (29.8%) 23 (24.7%) 22 (23.9%) 0.613
Baseline serum creatinine (mg/dl) 0.8 (0.7–0.9) 0.8 (0.7–1.0) 0.9 (0.8–1.0) 0.274
Baseline eGFR (ml/min/1.73  m2) 89 (78–101) 88 (75–100) 91 (77–105) 0.746
Non‑renal APACHE II 15 (10–20) 17 (10.5–22) 19 (12.5–24) 0.009
Non‑renal SOFA 5 (2–8) 5 (2–9) 8 (5–12) < 0.001
Charlson comorbidity index 3 (2–5) 3 (2–4) 4 (2–6) 0.566
Number of vasopressors/inotropes 0 (0–1) 1 (0–2) 2 (1–3) < 0.001
Mechanical ventilation (%) 44 (46.8%) 47 (50.5%) 62 (66.7%) 0.015
Serum creatinine at first renin measurement (mg/dl) 0.8 (0.7–1.5) 1.3 (0.8–2.4) 1.8 (0.9–3.3) < 0.001
Acute kidney injury (%) 30 (31.9%) 52 (55.9%) 63 (67.7%) < 0.001
 Stage  2a 2 (6.7%) 12 (23.1%) 8 (12.7%)
 Stage  3a 28 (93.3%) 40 (76.9%) 55 (87.3%)
Serum NGAL at first renin measurement (ng/ml) 119 (69–288) 226 (88–421) 240 (80–757) 0.018
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patients with AKI were receiving angiotensin convert-
ing enzyme inhibitors or angiotensin receptor blockers 
at enrollment. Serum renin values were markedly dif-
ferent in the three tertiles: first tertile 7.2 (3.1–12.4) pg/
ml, second tertile 40.7 (29.9–60.1) pg/ml, and third ter-
tile 355.3 (180.4–1032.1) pg/ml. While baseline kidney 
function was similar between the renin tertiles, patients 
in the highest tertile tended to more often be in the 
medical ICU, have liver disease, and be more acutely 
ill as suggested by non-renal APACHE II, non-renal 
SOFA, number of vasopressors/inotropes, requirement 
for mechanical ventilation, and have more severe AKI 
as assessed by serum creatinine and NGAL. The initial 
measurements of serum renin and NGAL were more 
than two-fold higher (p < 0.001 for both) in patients 
with AKI compared to those without AKI (Additional 
file 1: Table S1). At 5–7 days following this initial meas-
urement, both renin (p = 0.046) and NGAL (p < 0.001) 
remained higher in patients with AKI versus those 
without AKI (Additional file 1: Table S1). There was no 
significant interaction between the first serum renin 
measurement, AKI status, and the outcome of MAKE 
(p for interaction = 0.251).
For the primary outcome of MAKE assessed at hos-
pital discharge, increasing tertiles of serum renin were 
strongly associated with a greater frequency of MAKE 
events (p < 0.001) (Table  2). Increasing tertiles of serum 
renin were also associated with worse secondary out-
comes including need for inpatient KRT, duration of 
mechanical ventilation, and ICU and hospital lengths of 
stay (p ≤ 0.003 for all)    (Table 2). Patients experiencing 
MAKE had significantly higher serum renin and NGAL 
concentrations at both timepoints (p = 0.003 or less 
for all) (Additional file  1: Table  S2). When stratified by 
inpatient mortality, serum renin and NGAL measure-
ments were again higher at both time points measured 
in patients who died compared to those who survived 
(p < 0.001 for all) (Additional file  1: Table  S3). Serum 
renin concentrations are shown in Fig. 1.
In the multivariable logistic regression model for 
MAKE, the second [OR 2.51 (95% CI 1.08–5.80)] and 
third [OR 2.33 (95% CI 1.01–5.44)] renin tertiles were 
independently associated with MAKE when compared 
to the first renin tertile (Table 3). When the same model 
was analyzed using serum renin as a continuous vari-
able rather than categorization into tertiles, serum renin 
Table 2 Clinical outcomes by renin tertiles
MAKE major adverse kidney event, KRT kidney replacement therapy, eGFR estimated glomerular filtration rate, ICU intensive care unit
Outcome Tertile 1 (n = 94) Tertile 2 (n = 93) Tertile 3 (n = 93) p value
Primary outcomes
 MAKE at hospital discharge (%) 23 (24.5%) 36 (38.7%) 47 (50.5%) 0.001
 Hospital mortality 8 (8.5%) 10 (10.8%) 25 (26.9%) –
 KRT at discharge 1 (1.1%) 3 (3.2%) 4 (4.3%) –
 Discharge eGFR ≤ 75% of baseline 14 (14.9%) 23 (24.7%) 18 (19.4%) –
Secondary outcomes
 Inpatient KRT (%) 8 (8.5%) 16 (17.2%) 32 (34.4%) < 0.001
 Duration of mechanical ventilation (days) 0 (0–3) 1 (0–6) 2 (1–8) 0.003
 ICU length of stay (days) 4 (2–9) 6 (3–11) 8 (4–18) 0.001
 Hospital length of stays (days) 9 (5–17) 10 (5–18) 14 (8–22) 0.002
Fig. 1 Serum renin stratified by presence of acute kidney injury, major adverse kidney events, or inpatient mortality
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remained significantly and independently associated with 
MAKE (OR 1.19 (95% CI 1.01–1.41) for 1-log unit higher 
serum renin) (Additional file  1: Table  S4). In the multi-
variable logistic regression model for inpatient mortality, 
the third renin tertile, but not the second, was associated 
with in-hospital mortality: OR 2.98 (95% CI 1.03–8.61) 
(Additional file 1: Table S5). When the stepwise logistic 
regression model was limited to evaluation of MAKE in 
survivors only (KRT and reduced eGFR), renin was not 
significantly associated with MAKE (Additional file  1: 
Table S6). In a sensitivity analysis of the primary model, 
a 50% reduction in the eGFR threshold for MAKE rather 
than 25% reduction was evaluated (event numbers for the 
different definitions shown in Additional file 1: Table S7). 
Using the 50% eGFR reduction threshold, renin tertiles 
did not significantly associate with MAKE at discharge 
(Additional file 1: Table S8).
Renin as a continuous variable was further examined 
in a mixed linear model with repeated measures analy-
sis. The estimates and 95% CI were exponentiated back 
to geometric means and 95% CI presented. In the group 
of patients not experiencing MAKE, renin decreased 
significantly over time: geometric means decreased 
from 26 to 12 (p < 0.001) (Additional file 1: Table S9). In 
the group of patients experiencing MAKE, renin also 
decreased over time: geometric means decreased from 81 
to 39 (p = 0.002). There was no significant difference (no 
interaction) between groups for renin decrease over time 
for the outcome of MAKE (p = 0.745). In contrast, when 
analyzing mortality, there was an interaction (p = 0.041) 
between the mortality and survival groups for renin 
decrease over time (Additional file 1: Table S10). Patients 
surviving had a decreasing serum renin trend whereas 
patients that died had similar renin concentrations at the 
second time point compared to the first measurement.
To investigate the relative contribution of both AKI 
and hemodynamic instability to elevations in serum 
renin concentration, a 2 × 2 table with row and column 
comparisons is shown in Additional file  1: Table  S11. 
The receipt of vasopressors during the ICU admission 
was associated with elevated renin concentrations meas-
ured at the first time point, independent of AKI status. 
In addition, patients with AKI had higher serum renin 
concentrations compared to patients without AKI, inde-
pendent of the need for vasopressors during the ICU 
admission, although this comparison did not reach statis-
tical significance.
Discussion
In this multicenter prospective study, serum renin 
measured within the first days of ICU admission was 
significantly associated with MAKE. In particular, the 
association with hospital mortality appears to be the 
strongest association from the individual components 
of MAKE. This study adds to the body of literature sug-
gesting that the RAS, at least in the upstream portion 
represented by serum renin, is activated in critical ill-
ness and is associated with mortality and adverse kidney 
outcomes. The renin measurements in our study, par-
ticularly for patients with AKI and those experiencing 
MAKE, were much higher than their comparators, and at 
times, 10–100 × fold higher in comparison to renin levels 
from other patients in the study and the expected normal 
serum values.
The prior work in this field has primarily focused on 
critically ill patients with sepsis. In a cohort study of 30 
critically ill patients with severe sepsis compared to 10 
healthy controls, plasma renin activity (PRA) and angio-
tensin II were higher at 8- and 24-h following the recog-
nition of organ dysfunction. Furthermore, elevated PRA 
was negatively correlated with microvascular function 
as assessed using the reoxygenation rate of skeletal mus-
cle to reactive hyperemia using near infrared spectros-
copy [15]. While hypotension is known to elicit renin 
release, the mean arterial pressure in this study was not 
Table 3 Multivariable logistic regression model for major 
adverse kidney events at the time of hospital discharge by renin 
tertiles
eGFR estimated glomerular filtration rate, ICU intensive care unit, UK University 
of Kentucky, UTSW University of Texas Southwestern, APACHE II Acute Physiology 
and Chronic Health Evaluation II, NGAL neutrophil gelatinase-associated 
lipocalin
a Fixed model developed using hypothesized predictors of outcome and 
clinically relevant imbalances in renin tertiles
Variable Odds ratio with 95% 
confidence  intervala
p value
Renin tertile (vs. first tertile)
 Second tertile 2.51 (1.08–5.80) 0.032
 Third tertile 2.33 (1.01–5.44) 0.050
Age (vs. first quartile)
 Second quartile 0.32 (0.12–0.86) 0.023
 Third quartile 0.31 (0.10–0.95) 0.040
 Fourth quartile 0.30 (0.08–1.11) 0.071
Sex (male vs. female) 0.63 (0.32–1.25) 0.188
Race (vs. white)
 Black 2.30 (0.74–7.15) 0.150
 Other 1.20 (0.39–3.68) 0.748
Baseline eGFR, per 1 ml/min/1.73  m2 1.02 (0.99–1.04) 0.173
Charlson comorbidity index, per 1‑unit 1.64 (1.35–2.00) < 0.001
ICU (vs. surgical)
 Medical 2.82 (1.30–6.12) 0.009
 Cardiac 2.12 (0.69–6.48) 0.189
Site (UK vs. UTSW) 1.28 (0.54–3.02) 0.572
Non‑renal APACHE II, per 1‑unit 1.02 (0.98–1.06) 0.246
NGAL, per 1‑log unit 2.93 (2.02–4.23) < 0.001
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significantly correlated with PRA, suggesting that acti-
vated RAS in severe sepsis is due to altered explanations, 
perhaps either causally or even compensatory to micro-
vascular dysfunction and reduced tissue perfusion [15]. 
Renin is also known to be released in response to sym-
pathetic activation and metabolic alterations, which are 
common in critically ill patients in the ICU [16].
In a prospective study of 41 patients with septic shock 
requiring ≥ 0.25 mcg/kg/min of norepinephrine, plasma 
renin was much higher in patients with KDIGO stage 
2 or 3 AKI as compared to KDIGO stage 1 or no AKI 
[7]. This relationship has been difficult to tease apart 
as plasma renin is also moderately-strongly correlated 
with severity of illness scores, vasopressor dose, lactate, 
and similar markers [7]. Our results demonstrate that 
even controlling for these severity of illness indicators as 
well as kidney injury using serum NGAL, serum renin 
remains associated with MAKE. The challenge of further 
work in the field remains to ascertain whether elevated 
renin in the setting of critical illness remains a signal of 
damage at the microcirculatory level, or if elevated circu-
latory renin exerts untoward RAS-mediated effects that 
worsen the cycle of morbidity in AKI and other critical 
illness syndromes.
The concept of renin as a marker of tissue perfusion 
was recently tested in a single center study of 20 patients 
with 112 arterial blood samples and confirmed plasma 
renin was not affected by diurnal variation, medications, 
or removal by continuous renal replacement therapy 
(CRRT) [6]. Similar to our results, the authors demon-
strated renin levels with extreme elevation (> 100-fold 
upper limit of normal) in patients that did not survive. 
Additionally, renin outperformed lactate for predict-
ing ICU mortality [6]. Further, the value of repeated 
measures of renin in critical care settings remains unex-
plored. In our study, we noted that patients whose renin 
serum concentrations did not decrease by the second 
time measurement were more likely to die compared to 
surviving patients whose renin serum concentrations 
decreased. This difference in trajectories of the serum 
renin concentration was notable for mortality, but not for 
MAKE. However, in cardiac surgery patients, the change 
in serum renin concentrations from pre- and post-opera-
tion were recently shown to predict AKI better than the 
postoperative renin concentration alone [17]. These data 
all support the potential utility of repeated measures of 
circulatory renin.
Importantly, the assay technique for serum renin could 
significantly impact the findings. Previous literature uses 
both PRA and direct measurement of renin, both of 
which have trade-offs in their assessment. PRA results 
may be dependent on angiotensinogen which could be 
altered by comorbidities or medications in critically ill 
patients, and also has shown inter-laboratory variability 
[6, 18]. The measurement of renin in our study is unique 
from prior literature in this area in that the assay meas-
ures and directly quantifies active renin concentrations 
and shows low cross-reactivity for the precursor of renin, 
pro-renin [6]. While it has been shown that in stressed 
states, the renin release far exceeds increases in prorenin 
and that longer stimuli (i.e. not an acute stimuli) are 
required to impact prorenin levels, previous work meas-
uring total renin (renin and pro-renin) has been unable 
to distinguish the specific molecular increase of renin in 
critical illness [19, 20]. Our results confirm that active 
renin is elevated, and at times markedly elevated, in those 
patients with mortality and kidney injury from a broad 
etiology of critical illness syndromes. Interestingly, the 
prorenin receptor (PRR) binds both renin and prorenin, 
and may induce inflammatory and profibrotic gene 
expression via angiotensin-independent extracellular-sig-
nal-regulated kinase 1 (ERK1), ERK2, and p38 mitogen-
activated protein kinase (MAPK) signaling pathways [21, 
22]. This may provide yet another possible mechanism 
for renin to function in a causal detrimental pathway in 
critical illness rather than a marker of illness alone [21, 
22].
The statement that the RAS is over-activated in critical 
illness may, however, be an over-simplification of a com-
plex pathway. In a secondary analysis of the Angiotensin 
II for the Treatment of High-Output Shock (ATHOS-3) 
trial enrolling patients with refractory vasodilatory shock, 
significant ACE deficiency was hypothesized based on 
elevated angiotensin I: angiotensin II ratios of peptides 
[2]. Renin concentrations were shown to positively corre-
late with this angiotensin I: angiotensin II ratio, suggest-
ing that renin could be a surrogate marker in vasodilatory 
shock for a relative angiotensin II deficiency [23]. Renin 
concentrations rapidly fell in the group given exogenous 
angiotensin II, which supports this hypothesis [23]. Simi-
lar to our findings, renin was significantly associated with 
mortality in the ATHOS-3 study [23]. This concept of 
deficient angiotensin II signaling has been further sug-
gested in recent reports of sepsis-associated AKI [24]. 
Based on these conflicting reports of RAS over-activa-
tion throughout the traditional RAS axis [15], as well as 
those reviewed here suggesting incomplete activation in 
the traditional RAS axis, this may be an indication that 
different RAS endotypes exist in critical illness. If this is 
indeed the case, measuring renin is much closer to bed-
side application than the technically challenging meas-
urement of angiotensin peptides [5].
Strengths of this study include its prospective nature, 
standardized biospecimen collection at two time 
points, multicenter design, ruling out the influence 
of chronic kidney disease on the RAS by requirement 
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of documented baseline eGFR ≥ 60  mL/min/1.73   m2, 
careful consideration of covariates known to influence 
MAKE, measurement of active renin (as opposed to 
renin and prorenin), and broad generalizability to a range 
of critically ill patients. To our knowledge, this is the larg-
est study to date evaluating serum or plasma renin con-
centrations and outcomes in critically ill patients.
Our study also has important limitations. Due to the 
relatively large number of mortality events contribut-
ing to MAKE, we may have been under powered to 
detect an association with the kidney-specific outcomes 
in those patients surviving the hospital admission. This 
limitation is also suspected in the sensitivity analysis for 
MAKE using a 50% eGFR reduction from baseline where 
the number of eGFR events contributing to MAKE was 
reduced by almost half from the primary analysis. We 
also used a singular race-based eGFR estimate (assessed 
as ≤ 75% of baseline or not) to adjudicate part of the 
MAKE outcome. In general, eGFR equations were devel-
oped for evaluation of kidney functional status at steady 
state and are currently under revision by professional 
societies for their inclusion of race, which may have 
implications for studies using eGFR as a component of an 
outcome measure in subacute settings [25]. Importantly, 
our study did not enroll any patients with KDIGO stage 
1 AKI, an important group of patients with potentially 
reversible kidney injury in clinical practice. However, the 
latter is also advantageous to eliminate the confound-
ing effect of pre-renal azotemia as intrinsic AKI. While 
we adjusted for hemodynamic instability with non-renal 
APACHE II scores in multivariable modeling, as well 
as investigated the impact of vasopressor receipt while 
in the ICU on serum renin concentrations in additional 
analysis, future work would benefit from precise meas-
urements of vasopressor support in order to disentangle 
the contribution of shock (and vasopressor support) from 
AKI in terms of elevations in serum renin concentrations 
in critically ill patients. Additionally, RAS alterations in 
various diseases such as sepsis and post-operative con-
ditions may be unique, along with potential age and sex 
differences in the RAS that will be important avenues 
of future research [26, 27]. While a small proportion of 
patients were receiving RAS modulating drugs at enroll-
ment, the extent of pre-hospital use of RAS modulat-
ing drugs in this cohort is unknown. Even though the 
medications may have been stopped for several days 
before biospecimen collection, their impact on the renin 
response in critical illness is unclear. Finally, given the 
complexity of biospecimen collection in critically ill 
patients, renin measurements were not always obtained 
within the first 3 days of ICU admission, which may have 
shed additional light on temporal findings of the RAS in 
early stages of critical illness.
Conclusions
In a broad cohort of critically ill patients admitted to 
the ICU, early measurement of serum renin was sig-
nificantly and independently associated with MAKE 
assessed at hospital discharge. The association appears 
to be particularly strong for the relationship between 
higher serum renin measurements and inpatient mor-
tality. Further studies are needed to elucidate the value 
of renin as a surrogate pathobiologic marker of micro-
circulatory function during critical illness.
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